Back to results
US 10,473,661 B2Granted
Method for diagnosis, prognosis and determination of treatment for cutaneous T-cell lymphoma
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsLarisa J. Geskin, Brittany Lynn O'Neil Dulmage, Louis D. Falo, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
Claims8
A kit for diagnosing cutaneous T-cell lymphoma in a human subject, comprising:
- (i) a positive control sample, wherein the positive control sample has increased expression levels of TOX, PLS3, KIR3DL2, and GATA3, and decreased expression level of RUNX3, relative to the expression levels of TOX, PLS3, KIR3DL2, GATA3 and RUNX3 in a subject who does not suffer from cutaneous T-cell lymphoma;
- and
- (ii) nucleic acid primers for determining expression levels of TOX, PLS3, KIR3DL2, GATA3, and RUNX3 in a sample obtained from a human subject and in the positive control sample,
- wherein a diagnosis of cutaneous T-cell lymphoma is obtained when, in the sample obtained from the human subject and in the positive control, the determined expression level of TOX is more than 5 fold, the determined expression level of PLS3 is more than 10 fold, the determined expression level of KIR3DL2 is more than 5 fold, the determined expression level of GATA3 is more than about 1.75 fold, and the determined expression level of RUNX3 is less than about 60%, relative to the expression levels of a subject who does not suffer from cutaneous T-cell lymphoma.
1 more element
Dependencies are inferred from the claim text.